Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach

Antiviral Therapy

Volumn 10, Issue 1, 2005, Pages 157-166

  Jenwitheesuk, Ekachai ^a   Samudrala, Ram ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; PROTEINASE;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG BINDING; ENZYME INHIBITOR COMPLEX; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS MUTATION; X RAY CRYSTALLOGRAPHY; ANTIBIOTIC RESISTANCE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; METABOLISM; MUTATION; PROTEIN CONFORMATION; THERMODYNAMICS; VIROLOGY;

BINDING SITES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION; THERMODYNAMICS;

EID: 16244403666     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V & Mellors JW; AIDS Clinical Trials Group 398 Study Team. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. Journal of the American Medical Association 2002; 288:169-180.
2. Gallant JE. Strategies for long-term success in the treatment of HIV infection. Journal of the American Medical Association 2000; 283:1329-1334.
3. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283:381-390.
4. Hirsch MS & Richman DD. The role of genotypic resistance testing in selecting therapy for HIV. Journal of the American Medical Association 2000; 284:1649-1650.
5. Rusconi S, La Seta Catamancio S, Sheridan F & Parker D. A genotypic analysis of patients receiving zidovudine with either lamivudine, didanosine or zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215. Journal of Clinical Virology 2000; 19:135-142.
6. Frenkel LM, Wagner LE 2nd, Atwood SM, Cummins TJ & Dewhurst S. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. Journal of Clinical Microbiology 1995; 33:342-347.
7. Sugiura W, Shimada K, Matsuda M, Chiba T, Myint L, Okano A & Yamada K. Novel enzyme-linked mini-sequence assay for genotypic analysis of human immunodeficiency virus type 1 drug resistance. Journal of Clinical Microbiology 2003; 41:4971-4979.
8. Garcia Lerma J, Schinazi RF, Juodawlkis AS, Soriano V, Lin Y, Tatti K, Rimland D, Folks TM & Heneine W. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). Antimicrobial Agents & Chemotherapy 1999; 43:264-270.
9. Gonzalez R, Masquelier B, Fleury H, Lacroix B, Troesch A, Vernet G & Telles JN. Detection of human immunodeficiency virus type 1 antiretroviral resistance mutations by high-density DNA probe arrays. Journal of Clinical Microbiology 2004; 42:2907-2912.
10. Holodniy M, Katzenstein D, Winters M, Montoya J, Shafer R, Kozal M, Ragni M & Merigan TC. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. Journal of Acquired Immune Deficiency Syndromes 1993; 6:366-369.
11. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T & Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Journal of Clinical Microbiology 1999; 37:2291-2296.
12. Race E, Gilbert SM, Sheldon JG, Rose JS, Moffatt AR, Sitbon G, Dissanayeke SR, Cammack N & Duncan IB. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. AIDS 1998; 12:1465-1478.
13. Setti M, Bruzzone B, Ansaldi F, Borrelli P, Indiveri F & Icardi G. Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART. Journal of Medical Virology 2001; 64:199-206.
14. Sturmer M, Staszewski S, Doerr HW, Larder B, Bloor S & Hertogs K. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214. Antimicrobial Agents & Chemotherapy 2003; 47:54-61.
15. Kijak GH, Carobene MG & Salomon H. A highly prevalent polymorphism at codon 72 of HIV-1 reverse transcriptase in Argentina prevents hybridization reaction at codon 74 in the LiPA genotyping test. Journal of Virological Methods 2001; 94:87-95.
16. Rick SW, Topol IA, Erickson JW & Burt SK. Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease. Protein Science 1998; 7:1750-1756.
17. Wang W & Kollman PA. Computational study of protein specificity: the molecular basis of HlV-1 protease drug resistance. Proceedings of the National Academy of Sciences, USA 2001; 98:14937-14942.
18. Draghici S & Potter RB. Predicting HIV drug resistance with neural networks. Bioinformatics 2003; 19:98-107.
19. Wang D & Larder B. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. Journal of Infectious Disease 2003; 188:653-660.
20. Wang K, Jenwitheesuk E, Samudrala R & Mittler J. Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance. Antiviral Therapy 2004; 9:343-352.
21. Quigg M, Frost SD, McDonagh S, Burns SM, Clutterbuck D, McMillan A, Leen CS & Brown AJ. Association of antiretroviral resistance genotypes with response to therapy comparison of three models. Antiviral Therapy 2002; 7:151-157.
22. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, Korn K & Selbig J. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting pnenotype from genotype. Proceedings of the National Academy of Sciences, USA 2002; 99:8271-8276.
23. Cai CZ, Han LY, Ji ZL, Chen X & Chen YZ. SVM-Prot: web-based support vector machine software for functional classification of a protein from its primary sequence. Nucleic Acids Research 2003; 31:3692-3697.
24. Chen YZ, Gu XL & Cao ZW. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins? Journal of Molecular Graphics & Modelling 2001; 19:560-570.
25. Schaffer L & Verkhivker GM. Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization. Proteins 1998; 33:295-310.
26. Joseph-McCarthy D, Thomas BE 4th, Belmarsh M, Moustakas D & Alvarez JC. Pharmacophore-based molecular docking to account for ligand flexibility. Proteins 2003; 51:172-188.
27. Shenderovich MD, Kagan RM, Heseltine PN & Ramnarayan K. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Science 2003; 12:1706-1718.
28. Shafer RW, Stevenson D & Chan B. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 1999; 27:348-352.
29. Jenwitheesuk E & Samudrala R. Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations. BMC Structural Biology 2003; 3:2.
30. Bower M, Cohen FE & Dunbrack RL Jr. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. Journal of Molecular Biology 1997; 267:1268-1282.
31. Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, Phillips J, Shinozaki A, Varadarajan K & Schulten K. NAMD2: greater scalability for parallel molecular dynamics. Journal of Computational Physics 1999; 151:283-312.
32. Brunger AT. X-PLOR version 3.1, A System for X-ray Crystallography and NMR. 1992. New Haven, CT: Yale University Press.
33. Geller M, Miller M, Swanson SM & Maizel J. Analysis of the structure of HIV-1 protease complexed with a hexapeptide inhibitor. Part II: Molecular dynamic studies of the active site region. Proteins 1997; 27:195-203.
34. Piana S & Carloni P. Conformational flexibility of the catalytic Asp dyad in HIV-1 protease: An ab initio study on the free enzyme. Proteins 2000; 39:26-36.
35. Hyland LJ, Tomaszek TA Jr & Meek TD. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 1991; 30:8454-8463.
36. Yamazaki T, Nicholson LK, Torchia DA, Wingfield P, Stahl SJ, Kaufman JD, Eyermann CJ, Hodge CN, Lam PYS, Ru Y, Jadhav PK, Chang CH & Weber PC. NMR and X-rays evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protease and a non-peptide cyclic urea-based inhibitor. Journal of the American Chemical Society 1994; 116:10791-10792.
37. Grubmuller H, Heymann B & Tavan P. Ligand binding: molecular mechanics calculation of the streptavidin-biotin rupture force. Science 1996; 271:997-999.
38. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK & Olson AJ. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. Journal of Computational Chemistry 1998; 19:1639-1662.
39. Case DA, Darden TA, Cheatham, TE, III, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM, Wang B, Pearlman DA, Crowley M, Brozell S, Tsui V, Gohlke H, Mongan J, Hornak V, Cui G, Beroza P, Schafmeister C, Caldwell JW, Ross WS & Kollman PA. AMBER 8. 2004. San Francisco: University of California.